How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,078 results for

Physical Medicine

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Final recommendation statement: hormone therapy in postmenopausal women: primary prevention of chronic conditions.

in postmenopausal women who have had a hysterectomy. ( D recommendation ) Clinical Considerations Patient Population Under Consideration This recommendation statement applies to asymptomatic, postmenopausal women who are considering hormone therapy for the primary prevention of chronic medical conditions. It does not apply to women who are considering hormone therapy for the management of menopausal symptoms, such as hot flashes or vaginal dryness. It also does not apply to women who have had premature (...) by the U.S. Food and Drug Administration (FDA) in menopausal women are limited to the treatment of menopausal symptoms and the prevention of postmenopausal osteoporosis. An FDA-issued black box warning indicates that estrogen therapy, with or without progestin, should be prescribed at the lowest effective dose and for the shortest duration consistent with the patient's treatment goals and risks. Several different formulations of menopausal hormone therapy are approved by the FDA for use in the United

2017 National Guideline Clearinghouse (partial archive)

142. Pulp Therapy for Primary and Immature Permanent Teeth

Pulp Therapy for Primary and Immature Permanent Teeth AMERICAN ACADEMY OF PEDIATRIC DENTISTRY RECOMMENDATIONS: BEST PRACTICES 343 Purpose The American Academy of Pediatric Dentistry ( AAPD) intends these recommendations to aid in the diagnosis of pulp health versus pathosis and to set forth the indications, objectives, and therapeutic interventions for pulp therapy in primary and immature permanent teeth. Methods Recommendations on pulp therapy for primary and immature permanent teeth were (...) developed by the Clinical Affairs Com- mittee – Pulp Therapy Subcommittee and adopted in 1991. This document is a revision of the previous version, last revised in 2009. This revision included a new systematic literature search of the PubMed ® /MEDLINE database using the terms: pulpotomy, pulpectomy, indirect pulp treatment, stepwise excavation, pulp therapy, pulp capping, pulp exposure, bases, liners, calcium hydroxide, formocresol, ferric sulfate, glass ionomer, mineral trioxide aggregate (MTA

2014 American Academy of Pediatric Dentistry

143. Biologic therapy for psoriasis

relate to other factors (for example, other co-therapies or the underlying disease) that the risk of fetal abnormalities in women with psoriasis who conceive on biologic therapy has not been adequately studied and therefore cannot be áá British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 20 X For example XI There are no known interactions between biologic therapies and contraceptive methods (see drug-specific (...) of severe or unstable psoriasis if the biologic therapy were stopped · physical, psychological and social functioning if the biologic therapy were stopped · options for alternative, non-biologic treatment strategies áá R31 Assess whether biologic therapy for psoriasis can be stopped in women who become pregnant. Ensure consultation and information-sharing across specialities including with an obstetrician who has expertise in caring for pregnant women with medical problems. Collect pregnancy outcome

2017 British Association of Dermatologists

144. Occupational Therapy for people Undergoing total hip replacement

and successful interventions in the whole of medical practice. The success of hip replacement is entirely dependent upon a multidisciplinary team approach, with occupational therapy being a core part of its success. The updated guidance reflects changes in practice and in particular the requirement for reduction in length of stay. The trend for patients undergoing hip arthroplasty at younger ages continues, as does the increasing numbers of total hip replacements being performed year on year. National (...) . It is suggested that the return to physical and sporting activities is considered within an occupational therapy assessment and interventions. (Abe et al 2014 [C]; Cowie et al 2013 [C]; Harding et al 2014 [C]; Ollivier et al 2014 [C]; Vissers et al 2013 [C]; Wagenmakers et al 2011 [C]; Williams et al 2012 [C]; Wilson and Villar 2011 [D]) [New statement and evidence 2017] 2C 20. It is suggested that where specific needs are identified, the occupational therapist refers the service user on to community

2018 Publication 1554

145. Water Treatment Facilities, Dialysis Water and Dialysis Fluid Quality for Haemodialysis and Related Therapies

for the topics presented in the various sections of this document. The sources searched for full published papers were: Cochrane Database of Systematic Reviews – CDSR (Wiley) MEDLINE (Ovid) EMBASE (Ovid) PUBMED (NCBI) In addition the MAUDE database which houses medical device reports submitted to the FDA by mandatory reporters (Manufacturers, Importers and Device User Facilities) and the Medicines and Healthcare Regulatory Agency (MHRA) site for Alerts and Recalls for Drugs and Medical Devices were also (...) Water Treatment Facilities, Dialysis Water and Dialysis Fluid Quality for Haemodialysis and Related Therapies 1 Guideline on water treatment systems, dialysis water and dialysis fluid quality for haemodialysis and related therapies Clinical Practice Guideline Prepared on behalf of The Renal Association 1 and The Association of Renal Technologists 2 January 2016 Review Date January 2020 All feedback to NicholasHoenich 1,2 , Clinical Scientist, Newcastle University nahoenich

2016 Renal Association

146. Planning, initiation & withdrawal of Renal Replacement Therapy

Planning, initiation & withdrawal of Renal Replacement Therapy - 1 - CLINICAL PRACTICE GUIDELINE Planning, Initiating and Withdrawal of Renal Replacement Therapy UK Renal Association 6 th Edition Final Version (based on literature up to Feb 2013) Graham Warwick, Consultant Nephrologist Andrew Mooney, Consultant Nephrologist Lynne Russon, Consultant in Palliative Medicine, Rebecca Hardy, SpR in Nephrology Posted at Please check for updates Please send feedback (...) - 3.2 We recommend that patients who present with advanced kidney failure and are likely to need RRT within 3 months should be able to access an accelerated care pathway to deliver education, information and prepare for RRT. Patients presenting late or starting dialysis without any prior nephrology input should receive similar education and information about renal replacement therapies to inform long term choices (1D). 3.3 We recommend that all medically suitable patients should be informed about

2014 Renal Association

147. Antithrombotic Therapies in Spine Surgery

of representatives from physical medi- cine and rehab, pain medicine/management, or- thopedic surgery, neurosurgery, anesthesiology, rheumatology, psychology/psychiatry and family practice. Revisions to recommendations were con- sidered for incorporation only when substantiated by a preponderance of appropriate level evidence. ? Step 9: Submission for Board Approval After any evidence-based revisions were incorpo- rated, the drafts were prepared for NASS Board review and approval. Edits and revisions to recom (...) of clinically symptomatic DVT and/or PE (including fatal PE) following elective spinal surgery with one or more of the following prophylaxis measures: compression stockings, mechanical sequential compression devices, chemoprophylaxis medication? (PROGNOSTIC QUESTION) EFFICACY OF ANTITHROMBOTIC THERAPIES IN SPINE SURGERY ? Do prophylactic antithrombotic measures, including compression stockings, mechanical sequential compression devices and chemoprophylaxis medications, decrease the rate of clinically

2009 North American Spine Society

148. Therapies for essential tremor

, and other fine motor tasks. ET is a clinical diagnosis. Criteria for definite and probable ET include abnormal bilateral postural or kinetic tremor of the hands in the absence of other neurologic signs. Many clinicians accept isolated tremor of the head if there is no evidence of dystonia. Propranolol and primidone are commonly used to treat ET, although propranolol is the only medication that is approved by the Food and Drug Administration (FDA) for this purpose. It is estimated that at least 30 (...) treatment for limb tremor in ET, depending on concurrent medical conditions and potential side effects (Level A). 1Ai. Which drug should be used for initial treatment of ET? Three studies compared the initial efficacy of primidone and propranolol in reducing ET. One prospective, double-blind, randomized, placebo-controlled crossover study compared the effects of propranolol (maximum dose 40 mg three times a day), primidone (maximum dose 250 mg three times a day), and placebo in 14 patients with ET. Both

2005 American Academy of Neurology

149. Proton Beam Therapy Guidelines

Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein. Description and Application of the GuidelinesProton Beam Therapy | Copyright © 2018. AIM Specialty Health. All Rights Reserved. 4 Proton Beam Therapy Considerations Proton beam radiation therapy, also known as proton beam therapy (PBT), is a type of external radiation treatment. Using a stereotactic (...) outcomes with photon-based therapies, proton therapy will be considered not medically necessary. In situations where proton therapy is appropriate, PBT should be administered as monotherapy. Central Nervous System Lesions Radiation therapy is commonly used to treat central nervous system (CNS) tumors and other intracranial lesions such as arteriovenous malformations (AVM). Results of proton therapy have been reported for a variety of CNS lesions. In the treatment of gliomas, dose escalation to 68.2

2018 AIM Specialty Health

150. Neuroprotective strategies and alternative therapies for parkinson disease

; University of Kansas (G.G.), Kansas City; Division of Radiation Sciences (J.P.), Saint Louis, MO; University of Maryland Hospital (S.R.), Baltimore; Movement Disorder Center (T.Z.), Tampa, FL; and University of Maryland School of Medicine (W.J.W.), Baltimore. Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review) O. Suchowersky , G. Gronseth , J. Perlmutter , S. Reich , T. Zesiewicz , W. J. Weiner Neurology Apr 2006, 66 (7) 976-982; DOI (...) of PD is an important consideration of overall treatment. While the initiation of therapy has already been discussed in a previous Practice Parameter, many nonstandard pharmacologic and nonpharmacologic therapies are currently employed by patients and caregivers. One study found that 63% of patients with PD use nutritional supplements, but fewer than 50% of patients reported this use to their physicians ; only 4% were aware of possible drug supplement interactions. Additional nonpharmacologic

2006 American Academy of Neurology

151. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy (Full text)

and electrolyte balance, minimizing insensible water losses, and preventing infection. Given the immune mechanism of action of these medicines, use of immune suppression, such as with systemic corticosteroids, is warranted and should be offered, though the use of systemic corticosteroids has been more controversial for the treatment of SJS/TEN, in general. For DRESS/DIHS, high-dose and usually prolonged courses of systemic corticosteroids is first-line therapy following cessation of the offending drug (...) of Washington, and the Fred Hutchinson Cancer Research Center, Seattle, WA; and Tanyanika Phillips, CHRISTUS St Frances Cabrini Cancer Center, Alexandria, LA. Abstract Section: Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy. Methods A multidisciplinary, multi-organizational panel of experts in medical oncology, dermatology, gastroenterology, rheumatology

2018 American Society of Clinical Oncology Guidelines PubMed abstract

152. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement (Full text)

Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login (...) , including weight, blood glucose and lipid levels and blood pressure. Management of psychosis with its attendant medical problems requires a multidisciplinary approach, with primary health practitioners playing a central role. Mortality and medical morbidity is higher in those with psychosis than expected; preventive measures, combined with early detection and treatment of hyperglycaemia and other metabolic problems, is a key public health issue. A growing awareness of the physical health needs of people

2004 MJA Clinical Guidelines PubMed abstract

153. Treating erectile dysfunction after radical radiotherapy and androgen deprivation therapy (ADT) for prostate cancer

. • Assess other health problems/current medications which may affect sexual function. • Encourage adoption of exercise programme and lifestyle changes. • Start the ED rehabilitation programme early, and no later than 3-6 months after ADT or radiotherapy has commenced. • Consider combination therapy of PDE5-I tablets and vacuum erection device (VED) as first-line treatment. • Consider including daily low-dose PDE5-I tablets in ED rehabilitation programme. • Consider using the most effective PDE5-I (...) psychosexual therapy or couple counselling as appropriate. • Encourage the man to schedule regular sexual contact with or without intercourse, to assist the management of low desire. Re-assessment • Once ED management is initiated, re-assess treatment response at regular intervals preferably every three months. Treatment duration • Try PDE5-I drug/dose combination on at least eight occasions before switching to another drug/dose combination, unless patient reports adverse event warranting an early switch

2014 Prostate Cancer UK

154. Multiple gestation associated with infertility therapy: a committee opinion

Multiple gestation associated with infertility therapy: a committee opinion Multiple gestation associated with infertility therapy: an American Society for Reproductive Medicine Practice Committee opinion Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama The purpose of this committee opinion, which replaces the 2006 ASRM Practice Committee document titled Multiple Pregnancy Associated with Infertility Therapy (...) /American Society for Reproductive Medicine recommendation to limit the number of embryos transferred. Fertil Steril 2007;88:1554–61. 6. Centers for Disease Control and Prevention. Contribution of assisted reproductive technology and ovulation-inducing drugs to triplet and higher-order multiple births—US, 1980–1997. MMWR Morb Mortal Wkly Rep 2000;49:535–8. 7. WhiteC,WyshakG.Inheritanceinhumandizygotictwinning.NEnglJMed 1964;271:1003–5. 8. MacGillivray I. Epidemiology of twin pregnancy. Semin Perinatol

2012 Society for Assisted Reproductive Technology

155. The 2012 Hormone Therapy Position Statement of The North American Menopause Society

The 2012 Hormone Therapy Position Statement of The North American Menopause Society Menopause: The Journal of The North American Menopause Society Vol. 19, No. 3, pp. 257/271 DOI: 10.1097/gme.0b013e31824b970a * 2012 by The North American Menopause Society POSITION STATEMENT The 2012 Hormone Therapy Position Statement of The North American Menopause Society Abstract Objective: This position statement aimed to update the evidence-based position statement published by The North American Menopause (...) Society (NAMS) in 2010 regarding recommendations for hormone therapy (HT) for postmenopausal women. This updated position statement further distinguishes the emerging differences in the therapeutic benefit-risk ratio between estrogen therapy (ET) and combined estrogen-progestogen therapy (EPT) at various ages and time intervals since menopause onset. Methods: An Advisory Panel of expert clinicians and researchers in the field of women’s health was enlisted to review the 2010 NAMS position statement

2012 The North American Menopause Society

156. Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 14: Brace therapy as an adjunct to or substitute for lumbar fusion

included a low-back pain and bothersomeness scale (0–10), the Oswestry Dis- ability Index (ODI), and the physical and mental compo- nents of the 12-Item Short Form Health Survey (SF-12); administrative outcomes included medical visits and lost or restricted workdays due to injury or illness. It is un- certain whether randomization was attempted for all 868 workers. With respect to the 433 participants on whom the authors reported, it is uncertain at what time point the follow-up occurred for the self (...) [RMDQ]), change in pain VAS score, and consumption of analgesic and anti-inflammatory medications or muscle relaxants. At 30 days, patients in the study group had greater re- duction in functional disability (5.6 vs 4.0 on RMDQ, p = 0.02) and VAS (26.8 vs. 21.3, p = 0.04) than the con - trol group. These changes continued at 90 days (7.6 vs 6.1, p = 0.02, and 41.5 vs 32.0, p = 0.002). Consumption of pharmaceutical agents was reduced, as 34.3% of the study group and 56.8% of the control group took

2014 Congress of Neurological Surgeons

157. Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 13: Injection therapies, low-back pain, and lumbar fusion

Medical Center, Albert Einstein College of Medicine, Bronx, New York; 9 Department of Neurosurgery, Brigham and Women’ s Hospital, Boston, Massachusetts; 10 Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California; and 11 Department of Neurosurgery, Columbia University, New York, New York The medical literature continues to fail to support the use of lumbar epidural injections for long-term relief of chronic back pain without radiculopathy (...) Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 13: Injection therapies, low-back pain, and lumbar fusion J Neurosurg Spine 21:79–90, 2014 79 ©AANS, 2014 J Neurosurg: Spine / Volume 21 / July 2014 Therapeutic Recommendations There is no new evidence that conflicts with the pre - vious recommendations regarding injection therapies pub- lished in the original version of the “Guidelines for the per - formance of fusion procedures

2014 Congress of Neurological Surgeons

158. American College of Rheumatology Guidelines for Management of Gout Part 2: Therapy and Antiinflammatory Prophylaxis of Acute Gouty Arthritis

urate target has not yet been achieved. ? Oral colchicine is an appropriate ?rst-line gout attack prophylaxis therapy, including with appro- priate dose adjustment in chronic kidney disease and for drug interactions, unless there is a lack of tolerance or medical contraindication. ? Low-dose NSAID therapy is an appropriate choice for ?rst-line gout attack prophylaxis, unless there is a lack of tolerance or medical contraindication. fees, speaking fees, and/or honoraria (less than $10,000 each) from (...) , with further details, as expanded in other ?gures and tables, referenced in the ?gure and discussed in the text. ULT urate-lowering therapy; NSAID nonsteroidal antiin?ammatory drug; COX-2 cyclooxygenase 2; GI gastrointestinal; IL-1 interleukin-1. 1452 Khanna et alNSAIDs. For NSAIDs, the TFP recommended full dos- ing at either the Food and Drug Administration (FDA)– or European Medical Agency–approved antiin?ammatory/ analgesic doses used for the treatment of acute pain and/ or treatment of acute gout

2012 American College of Rheumatology

159. Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee

; intraarticular hyaluronate injections, duloxetine, and opioids were conditionally recommended in patients who had an inadequate response to initial therapy. Opioid analgesics were strongly recommended in patients who were either not willing to undergo or had contraindications for total joint arthroplasty after having failed medical therapy. Recom- mendations for hip OA were similar to those for the management of knee OA. Conclusion. These recommendations are based on the consensus judgment of clinical (...) received consultant fees (more than $10,000 each) from Abbott, Almirall, AstraZeneca, Aventis, Berlex, Biomatrix, Bristol-Myers Squibb, Caduceus Group, Centocor, Chelsea, Dimedix, Dimethaid, Eli Lilly, Glaxo- Welcome, GlaxoSmithKline, Hoechst Marion Roussel, Im- munomedics, Innovus, Johnson & Johnson, Larvol, Lilly Re- search, Medicine Group, Medicus, Merck, Merck Frosst, Novartis, Novopharm, Ortho McNeil, Pennside, P?zer, Roche, Sandoz, Scios, Searle, Teva Pharmaceuticals, UCB, and Wyeth Ayerst

2012 American College of Rheumatology

160. 2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities (Full text)

be available, the recommendations remain current. See the 2012 focused update for a complete review of the scope. 2. Indications for Pacing 2.1. Pacing for Bradycardia Due to Sinus and Atrioventricular Node Dysfunction In some patients, bradycardia is the consequence of essential long-term drug therapy of a type and dose for which there is no acceptable alternative. In these patients, pacing therapy is necessary to allow maintenance of ongoing medical treatment. 2.1.1. Sinus Node Dysfunction Sinus node (...) (Relevant) e343 2008 Reviewer Relationships With Industry and Other Entities (Relevant) e345 Abbreviations List ( UPDATED ) e347 2012 Author Relationships With Industry and Other Entities (Relevant) ( NEW ) e348 2012 Reviewer Relationships WithIndustry and Other Entities ( NEW ) e350 2012 Indications for CRT Therapy–Algorithm ( NEW ) e352 Preamble (UPDATED) It is important that the medical profession play a significant role in critically evaluating the use of diagnostic procedures and therapies

2012 American Heart Association PubMed abstract


Guidelines – filter by country